Put simply, colony stimulating factors
shift the body's white-blood-cell-making machinery into high gear.
The major product segments analyzed are Blood Growth Factors (Erythropoietins, Colony Stimulating Factors
, Interferons, & Interleukins), and Tissue Growth Factors.
Table 8: World Historic Review for Blood Growth Factors byType - Erythropoietins, Colony Stimulating Factors
,Interferons and Interleukins Markets Independently Analyzedwith Annual Sales Figures in US$ Million for Years 2003through 2008 (includes corresponding Graph/Chart) II-67
This study is focused on established segments in Europe including Erythropoietin, Granulocyte Colony Stimulating Factors
, Human Growth Hormones and emerging segments including monoclonal antibodies, Insulin and interferon.
Table 58: Colony Stimulating Factor
Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 55
CoGenesys is also developing Neugranin(TM), a long-acting form of Granulocyte Colony Stimulating Factor
(G-CSF), now in clinical testing as a treatment to decrease the incidence of infection in patients receiving myelosuppressive anti-cancer drugs, and Albulin-G, a long-acting form of insulin.
announced today the Company has submitted a Clinical Trial Application (CTA) to begin human studies in Europe of Neugranin(TM), a long-acting form of Granulocyte Colony Stimulating Factor
(G-CSF), which is designed to decrease the incidence of infection in patients receiving myelosuppressive anti-cancer drugs.
In addition, the Company is also advancing research on Gematide(TM), a peptide-based agonist of the Granulocyte Colony Stimulating Factor
receptor, and on Keratide(TM), a peptide-based agonist of the Keratinocyte Growth Factor receptor, and has entered into a research collaboration with EntreMed, Inc.
10, 2014 /PRNewswire/ -- This report analyzes the worldwide markets for Growth Factors (Blood and Tissue) in US$ Million by the following Types: Blood Growth Factors (Erythropoietins, Colony Stimulating Factors
, Interferons, & Interleukins), Tissue Growth Factors.
The European Agency for the Evaluation of Medicinal Products has already developed draft guidelines for generic versions of insulin, human growth factor, epoetin and colony stimulating factors
The picture is changing today and biotechnology feeds innovative ideas to the pharmaceutical industry to produce products such as recombinant human insulin, growth hormone, monoclonal antibodies, granulocyte colony stimulating factors
, erythropoeitin and interferon vaccines.
Biotechnology products already in use on the market include erythropoietin (EPO), granulocyte colony stimulating factors
, growth hormone (GH), human insulin, and tissue plasminogen activator (TPA).